Home » Digital therapeutics and Healt…

Thought Leadership

Read our insights and commentary about pharmaceutical industry news and healthcare innovation globally. Subscribe to our monthly newsletter to keep up to date with our thought leadership, news, and updates.

Showing 5 of 9 posts
September 27, 2021 | Blogs

AI-Based Software Paige Prostate is Granted FDA Approval Through the De Novo Regulatory Pathway

CBPartners' Digital Therapeutics & Health Technology Expertise Team summarizes the approval of the first AI-based software designed to identify areas of concern on a prostate biopsy image.

Image of Verily's office
August 30, 2021 | Blogs

Verily to Acquire SignalPath, Expanding the Company’s Clinical Research Capabilities

Verily recently announced its first major acquisition, a software platform known as SignalPath. The acquisition would fold SignalPath into Baseline, Verily’s clinical research platform.

April 14, 2021 | Blogs

Interview Series with Leaders of DTx: Challenges & Opportunities for Commercialization

In this three-part series, CBPartners’ Digital Therapeutics & Health Technology Expertise Team interviews some of the leaders of the digital therapeutics (DTx) space to collect their thoughts on the current challenges and opportunities for DTx commercialization.

KAISER’s recent systemic integration of digital health therapeutics (DTx) into the treatment paradigm for behavioral health
February 19, 2021 | Infographics

KAISER Integrates DTx Into the Behavioral Health Treatment Paradigm at No Extra Cost After a Clinician Referral

KAISER’s recent systemic integration of digital health therapeutics (DTx) into the treatment paradigm for behavioral health concerns is a step towards modernizing healthcare and represents a very structured approach to real-world data generation.

ICER released first cost-effective assessment for digital therapeutic
November 3, 2020 | Infographics

ICER Released First Cost-Effectiveness Assessment for a Digital Therapeutic (DTx)

Digital Therapies for Opioid Use Disorder (OUD) have been assessed by ICER to determine whether they are effective, both in terms of cost, and improvement in retention in treatment.